Hikma Posts Solid H1 Results, Reaffirms Strong Growth Outlook For 2025

Hikma Pharmaceuticals (HIK.L) reported a solid first half of 2025, with group revenue increasing 6% year-over-year to $1,658 million. Despite a 26% decline in reported operating profit due to a legal settlement and a 7% dip in core operating profit reflecting a strong prior-year comparator and product mix, profit attributable to shareholders rose 5% and basic EPS grew 6%. The company also increased its interim dividend by 12% to 36 cents and reaffirmed its full-year guidance for 4-6% revenue growth and core operating profit of $730-$770 million, signaling expectations for robust second-half performance.

Analysis

Hikma Pharmaceuticals reported a mixed but strategically coherent first half for 2025, characterized by solid top-line growth offset by anticipated pressure on profitability. Group revenue increased 6% year-over-year to $1.658 billion, meeting the company's full-year growth outlook. However, a significant 26% decline in reported operating profit to $259 million was primarily driven by a non-core legal settlement, an item investors may look through. More indicative of underlying performance, core operating profit fell 7% to $373 million, attributed to a challenging comparison with a strong 2024 and an unfavorable shift in product mix. Despite this, the company demonstrated shareholder-friendly capital allocation, raising its interim dividend by a substantial 12% to 36 cents per share. Crucially, management reaffirmed its full-year guidance for 4-6% revenue growth and core operating profit of $730-$770 million, signaling confidence in a robust second-half performance to meet these targets.

Key Decisions for Investors

• Investors should look past the 26% drop in reported operating profit, as it was distorted by a one-off legal settlement, and focus on the reaffirmed full-year guidance as the key indicator of expected performance.
• The 12% dividend increase is a strong signal of management's confidence in future cash flows and may provide a degree of valuation support for the stock.
• Monitor progress toward the full-year core operating profit target of $730-$770 million, as achieving this range will require a solid second-half performance to overcome the 7% decline seen in the first half.
• Consider the decline in core profitability due to product mix as a key risk factor to watch, as persistent margin pressure could challenge future earnings growth.